Designing Protein Contrast Agents for Precision MR Imaging (pMRI)
Conclusions: ProCAs exhibit super metal safety compared with all approved "safe" agents. Rapid development of pMRI platform technology and regulatory studies of ProCAs are expected to enable us to non-invasively determine the identity, quantity, and spatial location of the several major cancer cell types and their contribution to the heterogeneity of a tumor and its microenvironment. This will fill in the major gap with high translational capability which will have broad applications in medical diagnostics for early detection, monitoring progression, image-guided intervention, and drug development.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Yang, J. Tags: Preclinical Probes for Oncology Posters Source Type: research
More News: Cancer | Cancer & Oncology | Eye Cancers | HER2 | Liver | Melanoma | Nuclear Medicine | Ovarian Cancer | Ovaries | Prostate Cancer | Skin Cancer | Study | Toxicology | Urology & Nephrology | Uveal Melanoma